MARKET

HRTX

HRTX

Heron Therapeutics Inc
NASDAQ
2.680
-0.030
-1.11%
Closed 19:10 12/01 EST
OPEN
2.760
PREV CLOSE
2.710
HIGH
2.795
LOW
2.660
VOLUME
1.97M
TURNOVER
--
52 WEEK HIGH
10.46
52 WEEK LOW
2.190
MARKET CAP
318.62M
P/E (TTM)
-1.2843
1D
5D
1M
3M
1Y
5Y
Analysts Cut Price Targets As Heron Therapeutics' Zynrelef Disappoints In Q3
Benzinga · 11/09 18:15
Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $8
Benzinga · 11/09 11:47
--Needham Trims Price Target on Heron Therapeutics to $8 From $10, Maintains Buy Rating
--Needham Trims Price Target on Heron Therapeutics to $8 From $10, Maintains Buy Rating
MT Newswires · 11/09 10:19
Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 2.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/08 23:25
BRIEF-Heron Therapeutics Announces Financial Results For The Three, Nine Months Ended September 30, 2022
Reuters · 11/08 23:23
Heron Therapeutics reports Q3 results, affirms FY oncology care franchise revenue guidance
Seekingalpha · 11/08 21:47
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Highlights Recent Corporate Updates
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care, today announced financial results for the thre...
PR Newswire · 11/08 21:05
Earnings Outlook For Heron Therapeutics
Benzinga · 11/07 17:24
More
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.

Webull offers kinds of Heron Therapeutics Inc stock information, including NASDAQ:HRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HRTX stock methods without spending real money on the virtual paper trading platform.